Proteomic approaches in biomarker discovery: new perspectives in cancer diagnostics.
Proteomic approaches in biomarker discovery: new perspectives in cancer diagnostics.
复制标题
DOI：
10.1155/2014/260348
复制
发表时间：
2014
影响因子：
--
通讯作者：
Komel R
中科院分区：
文献类型：
--
作者：
Hudler P;Kocevar N;Komel R
尽管蛋白质组学方法取得了显著进展，包括提高了检测限和灵敏度，但这些方法尚未在常规临床实践中建立。阻止其整合到临床中的主要限制是设备的高成本、对训练有素的人员的需要，以及最后但并非最不重要的是，建立可靠和准确的蛋白质生物标志物或用于检测肿瘤的蛋白质生物标志物组。此外，大多数实体瘤的复杂性和异质性在发现特异性蛋白质特征方面存在障碍，所述特异性蛋白质特征可用于癌症的早期检测、用于预测疾病结果以及用于确定对特定疗法的反应。然而，癌症蛋白质组作为癌症发生和发展的病理过程的终点，可以代表发现新的生物标志物和定制治疗的分子靶点的重要来源。
Despite remarkable progress in proteomic methods, including improved detection limits and sensitivity, these methods have not yet been established in routine clinical practice. The main limitations, which prevent their integration into clinics, are high cost of equipment, the need for highly trained personnel, and last, but not least, the establishment of reliable and accurate protein biomarkers or panels of protein biomarkers for detection of neoplasms. Furthermore, the complexity and heterogeneity of most solid tumours present obstacles in the discovery of specific protein signatures, which could be used for early detection of cancers, for prediction of disease outcome, and for determining the response to specific therapies. However, cancer proteome, as the end-point of pathological processes that underlie cancer development and progression, could represent an important source for the discovery of new biomarkers and molecular targets for tailored therapies.
登录
查看更多内容
影响因子：
3.4
作者：
Asara, John M.;Christofk, Heather R.;Cantley, Lewis C.
通讯作者：
Cantley, Lewis C.
影响因子：
4.6
作者：
Bunn, Paul A., Jr.
通讯作者：
Bunn, Paul A., Jr.
影响因子：
30.8
作者：
Bell, DW;Gore, I;Haber, DA
通讯作者：
Haber, DA
影响因子：
5.1
作者：
Bu, Zhaode;Zheng, Zhixue;Ji, Jiafu
通讯作者：
Ji, Jiafu
影响因子：
46.9
作者：
Bhatia, Sangeeta;Frangioni, John V.;Polyak, Kornelia
通讯作者：
Polyak, Kornelia